Skip to main content
Clinical Trials/NCT04833309
NCT04833309
Completed
Not Applicable

Effectiveness and Safety of Pharmacopunture Therapy for Chronic Low Back Pain: A Pragmatic Randomized Controlled Trial

Jaseng Medical Foundation4 sites in 1 country100 target enrollmentJune 10, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Low-back Pain
Sponsor
Jaseng Medical Foundation
Enrollment
100
Locations
4
Primary Endpoint
Numeric rating scale (NRS) of low-back pain
Status
Completed
Last Updated
last year

Overview

Brief Summary

This is a multi-center, 2-arm parallel pragmatic randomized controlled trial that will compare pharmacopuncture therapy with physical therapy for chronic low back pain.

Detailed Description

This is a multi-center, 2-arm parallel pragmatic randomized controlled trial that will compare pharmacopuncture therapy with physical therapy for chronic low back pain. Participants who voluntarily signed informed consent form and eligible for the study were randomly assigned in a 1:1 ratio (50:50) for pharmacopuncture therapy group and physical therapy group. Participants of each group will receive total 5 weeks of intervention. This is a pragmatic randomized controlled trial, so physicians will have medical decision making according to each participant's conditions and choose the specific type and volume of pharmacopuncture and physical therapy.

Registry
clinicaltrials.gov
Start Date
June 10, 2021
End Date
February 26, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

In-Hyuk Ha, KMD

Director of Jaseng Spine and Joint Research Institute

Jaseng Medical Foundation

Eligibility Criteria

Inclusion Criteria

  • low back pain for more than 6 months
  • Numeric rating scale (NRS) score for low back pain 5 or more
  • 19-70 years old
  • participants who agreed and signed informed consent form

Exclusion Criteria

  • Spine metastasis of cancer, acute fracture of spine, or spine dislocation
  • Progressive neurologic deficits or severe neurologic deficits
  • Soft tissue diseases that can induce low back pain (ie. cancer, fibromyalgia, rheumatoid arthritis, gout, etc)
  • Presence of chronic underlying disease which can interfere the efficacy or interpretation (ie. stroke, myocardial infarct, kidney disease, dementia, diabetic neuropathy, epilepsy, etc)
  • Concurrent use of steroids, immunosuppressants, or psychotropic medications
  • Hemorrhagic disease, severe diabetes or taking anticoagulant drug
  • Participants who took NSAIDs or pharmacopuncture within 1 week
  • Pregnant or lactating women
  • Participants who had undergone lumbar surgery within 3 months
  • Participants who had participated in other clinical trial within 1 month, or have plan for participation in other trial during follow up period of this trial

Outcomes

Primary Outcomes

Numeric rating scale (NRS) of low-back pain

Time Frame: week 6

NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'.

Secondary Outcomes

  • Visual analogue scale (VAS) of leg radiating pain(week 1, 2, 3, 4, 5, 6, 13, 25)
  • Short Form-12 Health Survey version 2 (SF-12 v2)(week 1, 6, 13, 25)
  • Korean version of the Roland-Morris Disability Questionnaire (RMDQ)(week 1, 6, 13, 25)
  • Numeric rating scale (NRS) of low-back pain(week 1, 2, 3, 4, 5, 6, 13, 25)
  • Oswestry Disability Index (ODI)(week 1, 6, 13, 25)
  • Patient Global Impression of Change (PGIC)(week 6, 13, 25)
  • Numeric rating scale (NRS) of radiating pain in lower extremities(week 1, 2, 3, 4, 5, 6, 13, 25)
  • EuroQol-5 Dimension (EQ-5D-5L)(week 1, 6, 13, 25)
  • Visual analogue scale (VAS) of low-back pain(week 1, 2, 3, 4, 5, 6, 13, 25)

Study Sites (4)

Loading locations...

Similar Trials